action of glp-1 agonist Mechanisms of GLP-1RA Cardiovascular effects of Glucagon-like peptide
Description
doi:10.3390/cells9030740 178
Healthcare providers can address these concerns by discussing them with patients and weighing the potential benefits of GLP-1RAs therapy against the risks
Key Takeaways GLP-1 nausea is common but manageable with the right strategies
In addition, first oral GLP-1 receptor agonist (oral semaglutide) was recently approved ( Table 1
Payers and clinicians alike are beginning to treat obesity as a primary, chronic condition rather than a comorbidity, signaling a major shift in market dynamics
